Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Byooviz
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Fylnetra
    • Hadlima
    • Herzuma
    • Hulio
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Nyvepria
    • Ogivri
    • Ontruzant
    • Releuko
    • Renflexis
    • Retacrit
    • Riabni
    • Ruxience
    • Semglee
    • Trazimera
    • Truxima
    • Udenyca
    • Yusimry
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The 2023 Biosimilars Market Report
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

SM Health Comm

Recent Posts

  • Appeals Court Says “So What?” to Patent Thickets August 5, 2022
  • Coherus Scores Approval of Cimerli® as Interchangeable Ranibizumab Biosimilar August 4, 2022
  • A Conversation With Sonia T. Oskouei, PharmD, Vice President of Biosimilars, Cardinal Health: Part 2 August 2, 2022
  • A Conversation With Sonia T. Oskouei, PharmD, Vice President of Biosimilars, Cardinal Health July 29, 2022
  • New Systematic Review Gives Thumbs up to Biosimilar-to-Biosimilar Switching July 28, 2022
  • Sandoz Submits 351(k) Application for Biosimilar Natalizumab to Treat MS July 26, 2022
  • Prelaunch Adalimumab Updates Keep Coming: Sandoz’s Filing on Hyrimoz July 21, 2022
  • Self-Injectable Biosimilar Drugs and the Pharmacy Benefit July 13, 2022
  • Skinny Labels From the Attorney’s Perspective July 8, 2022
  • A Dispatch From the Biosimilar World of IP and Patents July 6, 2022

Recent Comments

Coherus Scores Appro… on Self-Injectable Biosimilar Dru…
A Conversation With… on Biosimilar-to-Biosimilar Switc…
New Systematic Revie… on A Profile on Lesser-Known Play…
A Conversation With… on New Systematic Review Gives Th…
New Systematic Revie… on Biosimilar Switching: The Evid…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • Biosimilar Approval Status
  • Further Dissecting the Launch of Adalimumab Biosimilars in the US
  • Who Are the Key Aflibercept Biosimilar Players to Watch?
  • The Evolution of the Biosimilars Market
  • The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
  • A Conversation With Sonia T. Oskouei, PharmD, Vice President of Biosimilars, Cardinal Health: Part 2
  • Self-Injectable Biosimilar Drugs and the Pharmacy Benefit
  • Ustekinumab Biosimilars Update
  • Phase 3 Data on Samsung Bioepis’ Eculizumab Biosimilar Confirms Equivalence to Soliris
  • Denosumab Biosimilar Competitors Gathering Data for February 2025 Launch
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2013-2022 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.